Insider Selling: Hologic, Inc. (HOLX) Director Sells 9,596 Shares of Stock
Hologic, Inc. (NASDAQ:HOLX) Director Lawrence M. Levy sold 9,596 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total transaction of $353,228.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Lawrence M. Levy also recently made the following trade(s):
- On Thursday, September 7th, Lawrence M. Levy sold 7,139 shares of Hologic stock. The stock was sold at an average price of $39.04, for a total transaction of $278,706.56.
Shares of Hologic, Inc. (HOLX) traded down 0.27% during midday trading on Thursday, hitting $36.56. 1,751,177 shares of the company traded hands. Hologic, Inc. has a 52 week low of $35.15 and a 52 week high of $46.80. The stock has a 50 day moving average of $37.70 and a 200-day moving average of $41.98. The stock has a market capitalization of $10.25 billion, a PE ratio of 13.62 and a beta of 0.91.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The company had revenue of $806.10 million for the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. Hologic’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.51 earnings per share. Equities analysts forecast that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.
Several hedge funds have recently bought and sold shares of HOLX. Hall Laurie J Trustee grew its position in Hologic by 10.2% during the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after acquiring an additional 225 shares during the last quarter. Commonwealth Bank of Australia grew its position in Hologic by 31.0% during the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after acquiring an additional 600 shares during the last quarter. MPS Loria Financial Planners LLC bought a new position in Hologic during the second quarter valued at approximately $191,000. National Asset Management Inc. bought a new position in Hologic during the second quarter valued at approximately $203,000. Finally, Miles Capital Inc. bought a new position in Hologic during the first quarter valued at approximately $206,000. Institutional investors own 96.38% of the company’s stock.
A number of equities analysts recently commented on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $49.00 price target on shares of Hologic in a research report on Wednesday, June 28th. Bank of America Corporation reaffirmed a “neutral” rating and set a $48.00 price target (up from $44.00) on shares of Hologic in a research report on Friday, July 21st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $51.00 price target on shares of Hologic in a research report on Friday, July 14th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Hologic in a research report on Friday, July 14th. Finally, BidaskClub lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the stock. Hologic has a consensus rating of “Hold” and a consensus price target of $47.77.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.